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Abstract
Background: Chronic plantar ulcers are common problems for leprosy patients with numb 
feet due to their prolonged healing time. Chronic plantar ulcers affect the quality of life 
of patients and can lead to more serious complications, such as disability and deformity, if 
not handled appropriately. Wound‑care products in the market, however, give unsatisfactory 
results. One factor in the delayed healing of chronic plantar ulcers due to leprosy is the lack 
of growth factors and cytokines in the wound due to reduced blood supply. We speculated 
that application of human amniotic membrane stem cell (hAMSC) secretome, which contains 
growth factors and cytokines, could improve wound healing. Aim: To evaluate the effect of 
topical application of a hAMSC secretome gel on wound healing of chronic plantar ulcers due 
to leprosy. Materials and Methods: We recruited 11 patients after leprosy treatment with 
chronic plantar ulcers due to leprosy. hAMSC secretome gel was applied topically to ulcers 
every 3 days for up to 2 months. Ulcer size and possible side effects or complications from gel 
application were evaluated weekly. Results: The ulcers of 8 of 11 patients (72.7%) completely 
healed, the ulcers of 2 patients (18.2%) partially healed, and the ulcers of 1 patient (9.1%) 
persisted. No ulcers became worse. Conclusion: hAMSC secretome was found to be an 
efficacious and well‑tolerated alternative therapy for chronic plantar ulcers due to leprosy.
Key Words: Human amniotic membrane stem cell secretome, leprosy chronic plantar ulcers, 
wound healing
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Introduction
Plantar ulcers are a serious complication of leprosy 
and are categorized by the World Health Organization 
as a grade 2 disability, that is, “visible deformity or 
damage present.”[1] Plantar ulcers are a serious health 
problem because healing is usually slow, often leading to 
chronic ulceration. Chronic ulcers result from repeated 
trauma due to sensory impairment, muscular paralysis, 
autonomic nerve impairment, callus formation, and 
superinfection.[2,3] Slow healing of chronic ulcers is 
likely exacerbated by the lack of growth factors and 
blood supply in the wound due to autonomic nerve 
impairment.[4,5] Wound healing is a dynamic process 
that requires coordination between cells, growth factors, 
cytokines, and the extracellular matrix.[6,7] Wound care 
products in the market and daily practice regarding 
wound management seem to give unsatisfactory results 
because they do not supply growth factors and cytokines.
Stem cell therapy has recently gained substantial 
interest. In stem cell therapy, stem cells grow into 
the injured tissue and differentiate into specialized 
cells, secreting various growth factors and cytokines; 
these secreted factors are referred to as the stem 
cell secretome. In vitro, stem cell secretomes can be 
harvested from used stem cell growth medium. Stem 
cell secretomes alone are now being applied in areas 
of regenerative medicine including chronic wound 
therapy.[8,9]
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Human amniotic membrane stem cells (hAMSCs) have 
high proliferative and immunomodulatory activities. 
Both fresh and freeze‑dried human amniotic membrane 
have been effectively used to assist wound healing, 
likely driven by the regenerative growth factors and 
cytokines produced by hAMSC. These growth factors 
and cytokines are also found in the hAMSC secretome, 
suggesting that the secretome alone could be used as a 
treatment modality for wound healing.[10‑12]
Here, we describe a work to evaluate the contribution 
of application of a hAMSC secretome gel for healing of 
leprosy chronic plantar ulcer wounds.
Materials and Methods
Study design and participants
Our descriptive study monitored the effect of a 
2‑month hAMSC secretome gel treatment course on 11 
subjects in the Dermato‑Venereology outpatient clinic 
of Dr. Soetomo General Hospital, Surabaya between 
November 2015 and April 2016. The study was approved 
by the Ethical Committee Board of Dr. Soetomo General 
Hospital Surabaya, and informed consent was obtained 
from all subjects.
Eleven subjects with plantar ulcers due to leprosy after 
leprosy treatment were recruited based on the following 
criteria:
Inclusion criteria
•	 Patients	 who	 had	 a	 chronic	 plantar	 ulcer	 resulting	
from leprosy for at least 6 weeks
•	 Ulcer	 no	 larger	 than	 9	 cm2 and no deeper than 
0.5 cm
•	 Ulcer	 which	 lacked	 complications;	 with	 no	
surrounding erythema, no swelling, did not cause 
acute pain, the surrounding skin was not warm upon 
examination by palpation, ulcer which lacked wound 
sinuses, and no tendons or bones were exposed
•	 Patients	who	were	in	otherwise	good	general	health
•	 Patients	willing	to	sign	their	informed	consent.
Exclusion criteria
•	 Patients	 who	 had	 used	 a	 systemic	 corticosteroid	 in	
the previous 2 weeks.
•	 Patient	 with	 a	 history	 of	 hemophilia,	 blood	 clotting	
disorders, or antiplatelet consumption.
•	 Patient	with	a	history	of	hypersensitivity	to	adhesive	
bandage.
Preparation of hAMSC secretome gel
The Stem Cell Laboratory at the Institute of Tropical 
Disease, Airlangga University, Indonesia, provided hAMSC 
secretome samples. Donor procedures and stem cells 
were handled according to the international standard for 
human stem cell culture.
Because the hAMSC secretome was obtained in liquid 
form, effective application to a wound required that 
we first made it viscous. We made a hAMSC secretome 
gel by adding alginate acid sodium from brown algae 
(Phaeophyceae), choosing alginate because of its 
hypoallergenicity. To make a hAMSC secretome gel of 
appropriate viscosity, 0.08 g of alginate acid sodium 
was added per milliliter of secretome medium.[13] The 
resulting hAMSC secretome gel was stored refrigerated 
for up to 1 month, avoiding exposure to direct sunlight 
and temperatures exceeding 37°C.
Study procedures
At the beginning of the study, all ulcers underwent 
surgical debridement, had their baseline widths and 
depths recorded, and were photographed. Secretome 
gel was applied to ulcers every 3 days for up to 
2 months. After gel application, ulcers were covered 
with transparent film dressing followed by an adhesive 
bandage. Ulcers were evaluated every week: the width 
and depth of the ulcer were measured, direct or indirect 
side effects or complications due to gel application 
assessed, and photographs taken of the ulcer.
We anticipated allergic contact dermatitis resulting 
in ulcer deterioration as a possible complication of 
our study. It was decided that in case such events 
were to occur, gel application would be stopped and 
complications managed. To preemptively minimize 
complication risk, study participants were asked to avoid 
long periods of standing or walking and were not given 
tasks involving carrying or unloading heavy weights.
Figure 1: The mean percentage of wound healing every week
Figure 2: (a) Before treatment. (b) Second week after treatment. (c) Ulcer completely 
healed on third week after treatment
cba
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Results
We recruited more male subjects than female subjects, 
with a mean age of 49.64 ± 8.31 years. Subjects on average 
had ulcers for 2.22 ± 1.83 years, and the average width of 
ulcers at the start of the study was 1.64 ± 0.84 cm2. All 
subjects were present for the entire duration of the study. 
Patient demographics and ulcer characteristics at the start 
of the study are listed in Table 1.
At the end of the study, the ulcers of eight patients 
(72.7%) had completely healed, those of two patients 
(18.2%) had improved, and those of one patient 
persisted; no ulcers got worse. The percentage of healing, 
measured by the percentage size reduction of ulcers, 
increased every week [Figure 1]. The average reduction 
of the width and depth of ulcers at the end of the study 
was 78.64% ± 39.63% and 86.82% ± 30.19%, respectively. 
Over the course of the study, the mean reduction in 
the width of ulcers was 1.45 ± 0.84 cm2, and the mean 
reduction in the depth of ulcers was 0.35 ± 0.16 cm.
The characteristics of participants and the degree of 
ulcer healing are tabulated in Table 2. None of the 
participants experienced adverse effects or complications 
from the study. The progression of ulcers before and 
after treatment is shown in Figure 2.
Discussion
Management of chronic plantar ulcers due to leprosy 
is challenging because ulcers take a long time to 
heal, the treatment affects patients and their families 
socioeconomically, and it is frustrating to patients. 
Many kinds of wound management have been developed 
to tackle these challenges, including the application of 
stem cell secretome as described in this study.
Our results showed that hAMSC secretome gel improved 
healing rates of chronic plantar ulcers. In the majority 
of subjects (72.7%), ulcers completely healed; in 
Table 1: Patient demographics and ulcer baseline 
characteristics
Variable Subjects (n=11), n (%)
Sex
Male 5 (45.5)
Female 6 (54.5)
Age (years)
25‑50 6 (54.5)
>50 5 (45.5)
Duration of ulcer (years)
<1 3 (27.3)
1‑5 7 (63.6)
>5 1 (9.1)
Width of ulcers at baseline (cm2)
<1 1 (9.1)
1‑4 10 (90.9)
Location of plantar ulcers
Forefoot 10 (90.9)
Midfoot 1 (9.1)
Body weight of subjects (kg)
50‑60 4 (36.4)
61‑70 6 (54.5)
>70 1 (9.1)
Table 2: Characteristics of participants whose ulcer completely healed, partially healed, and persisted
Variable Completely healed (n=8) Partially healed (n=2) Persisted (n=1)
Sex
Male 3 2 0
Female 5 0 1
Age (years)
21‑50 4 1 1
>50 4 1 0
Duration of ulcer (years)
<1 3 0 0
1‑5 5 1 1
>5 0 1 0
Width of ulcers at baseline (cm2)
<1 1 0 0
1‑4 7 2 1
Location of the ulcers
Forefoot 7 2 1
Midfoot 1 0 0
Body weight of participants (kg)
50‑60 4 0 0
61‑70 3 2 1
>70 1 0 0
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18.2% subjects, ulcers partially healed; and in one 
subject, ulcer persisted. In no case did ulcers worsen. 
Additionally, none of the subjects experienced side 
effects or complications.
There are many causes of chronic ulcers, including 
prolonged inflammatory conditions, elevated protease 
activity, and decreased growth factor concentrations. 
We note that hAMSC secretome gel contains various 
paracrine factors, including growth factors and cytokines. 
Application of this secretome gel may function by 
improving the conditions of the wound microenvironment 
and thus encouraging healing. Cytokines in the hAMSC 
secretome gel will act on the inflammatory phase of 
wound healing proinflammatory cytokines will treat any 
infection in the wound, while antiinflammatory cytokines 
will reduce the inflammation process. Simultaneously, 
growth factors in the hAMSC secretome gel will contribute 
to the proliferation phase of wound healing by inducing 
angiogenesis and stimulating cell proliferation for the 
epithelialization process of wound healing.[9,14‑16]
To remove calluses and necrotic tissues, surgical 
debridement was performed on all patients before 
application of the gel. Removing calluses and necrotic 
tissues is important for management of wound healing 
because they could be a source of infection that might 
inhibit the healing process. Calluses also exert continuous 
pressure on the ulcer and inhibit epithelialization during 
wound healing.[3]
In conclusion, hAMSC secretome gel was beneficial to 
treatment of chronic plantar ulcers due to leprosy. 
Additional controlled prospective clinical trials, however, 
will be necessary to definitively demonstrate its efficacy.
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